Trial Profile
The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Expanded access; Therapeutic Use
- Acronyms EMBRACE
- Sponsors Alexion Pharmaceuticals
- 19 Jun 2017 New trial record